Last reviewed · How we verify
Aricept
At a glance
| Generic name | Aricept |
|---|---|
| Also known as | Donepezil (generic name), Donepezil HCl, Donepezil Hydrochloride (generic name), Aricept Tablet |
| Sponsor | Eisai Korea Inc. |
| Target | Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Alzheimer's disease
- Moderate to Severe Alzheimer's Type Dementia
Common side effects
- Nausea
- Diarrhea
- Insomnia
- Vomiting
- Muscle cramps
- Fatigue
- Anorexia
Key clinical trials
- Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease (PHASE2)
- Donepezil Versus Non-drug Treatment in Alzheimer's Disease. (PHASE3)
- Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease (NA)
- Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease (NA)
- Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (PHASE1)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
- Effect of Donepezil on Speech Recognition in Cochlear Implant Users (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |